In sharp contrast to earlier studies, patients with severe triple-vessel heart disease fared equally well whether they ...

Cotemporary DES paired with FFR guidance and modern medical therapy may be what narrowed the gap, William Fearon says.

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today they have entered a non-binding Memorandum of ...

The following is a summary of "Transit time flow management as a management strategy in high-risk groups undergoing coronary ...

Compared with other studies, the differences in outcomes between percutaneous coronary intervention (PCI) and coronary artery ...

Advances in PCI over the past decade mean the procedure can now approximate results only previously achieved with open-heart bypass surgery, new data show.